This prospective, multi-center, observational study will evaluate factors influencing the use of RoActemra/Actemra (tocilizumab) as monotherapy in rheumatoid arthritis patients in real life setting. Data will be collected from patients for 12 months following initiation of RoActemra treatment.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01474291?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
